Metoclopramide

Metoclopramide is a potent antagonist of 5-HT3 and dopamine D2 receptor, with IC50s of 308 nM and 483 nM, respectively. Metoclopramide can be used for the research of nausea and vomiting, gastro-oesophageal reflux, and gastroparesis[1][2].

Product Specifications

CAS Number

[364-62-5]

UNSPSC

12352005

Hazard Statement

H302

Target

5-HT Receptor; Dopamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Field of Research

Endocrinology

Assay Protocol

https://www.medchemexpress.com/Metoclopramide.html

Purity

99.98

Solubility

DMSO : 110 mg/mL (ultrasonic)

Smiles

O=C(NCCN(CC)CC)C1=CC(Cl)=C(N)C=C1OC

Molecular Formula

C14H22ClN3O2

Molecular Weight

299.80

Precautions

H302

References & Citations

[1]Hirokawa Y, et, al. Synthesis and structure-activity relationships of 4-amino-5-chloro-N- (1,4-dialkylhexahydro-1,4-diazepin-6-yl) -2-methoxybenzamide derivatives, novel and potent serotonin 5-HT3 and dopamine D2 receptors dual antagonist. Chem Pharm Bull (Tokyo) . 2002 Jul;50 (7) :941-59.|[2]Rao AS, et, al. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010 Jan;31 (1) :11-9.|[3]Edwards CR, et, al. In vivo and in vitro studies on the effect of metoclopramide on aldosterone secretion. Clin Endocrinol (Oxf) . 1980 Jul;13 (1) :45-50.|[4]Bhosale KB, et, al. Dose-dependent response of central dopaminergic systems to metoclopramide in mice. Indian J Exp Biol. 1997 Jun;35 (6) :618-22.|[5]Gomes RCT, et, al. Effects of metoclopramide on the mouse anterior pituitary during the estrous cycle. Clinics (Sao Paulo) . 2011;66 (6) :1101-4.